-
Take a look at www.trichomoniasis.net, the first comprehensive web site to focus on the sexually transmitted disease (STD) trichomoniasis.
-
No doubt you have scanned news reports of a recent study of male circumcision, used as an HIV prevention intervention, which resulted in dramatic reduction in HIV incidence among circumcised men.1 But does the news translate into an immediate change in public health policy?
-
The manufacturer of the abortion pill mifepristone (Mifeprex, Danco Laboratories; New York City) has revised the safety information for the drugs label and issued a letter to health care providers in light of five deaths from serious bacterial infection and sepsis following use of the medication abortion regimen.
-
New evidence indicates that women with benign breast disease have a higher risk for breast cancer, and that certain types of breast disease may predict the near-term development of breast cancer.
-
In reviewing the chart for your next patient, you note that she is a 28-year-old woman with epilepsy. What information do you need to provide her when it comes to contraceptive choices? Many family planning clinicians encounter this scenario. Epilepsy is one of the most common chronic health conditions affecting reproductive-age women.
-
Consider these facts: Women are the fastest-growing group in the United States with newly diagnosed HIV, and last year, an estimated 6,000-7,000 women with HIV gave birth.
-
Vlachopoulos et al studied 17 healthy non-smoking adults (mean age 29), who were free from vasculopathies such as diabetes, hyperlipidemia, or family history of premature vascular disease.
-
Legro and colleagues followed 71 women with polycystic ovary syndrome and 23 normal women with regular menses for 2 to 3 years. Impaired glucose tolerance increased in prevalence during the follow-up period in the women with polycystic ovaries, from 37% with impaired tolerance and 10% with type 2 diabetes mellitus at baseline to 45% and 15%, respectively.
-
Golden and colleagues compared alendronate treatment (10 mg daily) with placebo in a randomized clinical trial, in 32 female adolescents with anorexia nervosa. In addition, every participant was supplemented with calcium and vitamin D.
-
This is a prospective trial in which the levonorgestrel-releasing IUD was used in 16 patients who had an inherited bleeding disorder including 13 with von Willebrands disease and 2 with factor XI deficiency. No pelvic pathology was identified in any patient.
